Heart failure (HF) affects an estimated 5.7 million Americans, and the incidence increases in the older population.12 Nearly half of those affected have systolic HF.13,14* Learn about Atacand, used as an adjunct to conventional heart failure treatments like ACE inhibitors and beta-blockers, in reducing the risk of cardiovascular (CV) death among adult patients with systolic heart failure (NYHA Classes II-IV with LVEF ≤40%).
*Atacand is indicated for the treatment of systolic heart failure in adult patients with NYHA Classes II-IV with LVEF ≤40%.1
Examine results of the CHARM low-LVEF trials and the effect that Atacand, a once-daily angiotensin II type-1 receptor blocker (ARB), in addition to conventional HF therapies, produced in both CV mortality and hospital admissions for heart failure (HF) in a broad spectrum of patients.9
Results of the CHARM low-LVEF trials showed that adding the angiotensin II type-1 receptor blocker (ARB) Atacand to conventional heart failure (HF) therapies reduced both cardiovascular (CV) mortality and hospital admissions for chronic heart failure in a broad spectrum of adult patients with heart failure (NYHA classes II-IV) with low left-ventricular ejection fraction (LVEF) ≤40%.
Atacand is FDA-approved to reduce cardiovascular (CV) death in heart failure (HF) when added to conventional heart failure treatment.1-8
Individual ARBs may have additional approved uses. See full Prescribing Information of each ARB for full indications. Diovan is a registered trademark of Novartis Pharmaceuticals Corporation. Avapro is a registered trademark of Bristol-Myers Squibb Sanofi-Synthelabo Partnership. Benicar is a registered trademark of Daiichi Sankyo, Inc. Cozaar is a registered trademark of Merck & Co., Inc. Micardis is a registered trademark of Boehringer Ingelheim International GmbH. Teveten is a registered trademark of Biovail Pharmaceuticals, Inc. Edarbi is a registered trademark of Takeda Pharmaceutical Company Limited, licensed by Arbor Pharmaceuticals, LLC.
Overview of clinical trials studying angiotensin receptor blockers (ARBs) in chronic systolic heart failure.
ATACAND HCT is not approved for treatment of heart failure.
This product information is intended for US health care professionals only.
Atacand and Atacand HCT are registered trademarks of the AstraZeneca group of companies. ©2016 AstraZeneca. All rights reserved. 2005404-3250804 Last Updated 6/16
Manufactured under the license from Takeda Pharmaceutical Company, Ltd. by: AstraZeneca AB, S-151, 85 Södertälje, Sweden